Idebenone for Health & Longevity - Quick Reference Sheet

Idebenone for Health & Longevity

Created on 07/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A lab-made, better-absorbed relative of a natural energy-supporting compound. Its one well-proven benefit is narrow: protecting and partly restoring sight during attacks of a rare inherited eye disease. Its promise for energy, brain, and healthy aging rests on theory and animal work, not human results. Remarkably well tolerated; long-term safety in healthy people unstudied. (Full Review)

Protocol

Dose (Longevity)
45–300 mg/day
Off-label wellness range; no consensus optimal dose
Timing
With meals, earlier in day
Take with fat-containing food; morning and midday to avoid sleep interference
Dosing Schedule
Split 2–3× daily
Short half-life favors divided doses over one large dose
Time to effect
Vision (LHON)
Months
Visual change unfolds over months of continuous use, not days
Skin (Topical)
4–6 weeks
Appearance of sun-damaged skin improves in small studies
Energy / Antioxidant
No set timeline
No validated timeline; subjective changes are gradual

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Significant liver impairment (Child-Pugh Class C)
  • Known hypersensitivity to idebenone
  • Children (except under specialist supervision)
Key Interactions
  • CYP3A4 substrates (e.g., simvastatin, midazolam, tacrolimus)
  • High-dose NSAIDs (ibuprofen, naproxen)
  • Additive antioxidant/mitochondrial supplements (CoQ10, vitamin E, alpha-lipoic acid, N-acetylcysteine)

Risk & Side Effects

  • High: Mild gastrointestinal effects; reddish-brown urine discoloration
  • Medium: Upper respiratory symptoms and cough; headache and dizziness
  • Low: Elevated liver enzymes; pro-oxidant and Complex I inhibition at high concentrations
  • Speculative: Unknown long-term safety in healthy aging adults; theoretical interaction-related adverse events

Monitoring

Marker Target Why
ALT ~10–26 U/L Detects liver stress from a liver-metabolized compound
AST ~10–26 U/L Complements ALT to assess liver strain
GGT <20 U/L Sensitive marker of hepatic and oxidative stress
Fasting glucose 75–90 mg/dL General metabolic health context
hs-CRP <1.0 mg/L Tracks systemic inflammation and oxidative burden
Visual acuity / OCT Stable or improving from baseline Direct efficacy measure in LHON use

Cadence: Liver enzymes at 4–8 weeks, then every 3–6 months; for LHON, vision and retinal imaging at 3, 6, and 12 months, then periodically

Qualitative Assessment

  • Subjective energy and stamina through the day
  • Cognitive clarity and mental focus
  • Exercise tolerance and recovery
  • For LHON specifically, stabilization or improvement in central vision
  • Absence of new side effects such as persistent gastrointestinal upset